Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
84
SHC Quote, Financials, Valuation and Earnings
Last price:
$17.70
Seasonality move
:
18.76%
Day range:
$17.35 - $17.83
52-week range:
$9.53 - $17.83
Dividend yield:
0%
P/E ratio:
91.71x
P/S ratio:
4.39x
P/B ratio:
9.13x
Volume:
1.1M
Avg. volume:
2.6M
1-year change:
30.63%
Market cap:
$5B
Revenue:
$1.1B
EPS (TTM):
$0.19
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SHC
Sotera Health Co.
|
$303.7M | $0.22 | 3.04% | 462.3% | $18.93 |
|
FONR
FONAR Corp.
|
-- | -- | -- | -- | -- |
|
PRPH
ProPhase Labs, Inc.
|
$3.6M | -$0.15 | 3.99% | -50% | $13.80 |
|
TMO
Thermo Fisher Scientific, Inc.
|
$10.9B | $5.50 | 4.89% | 35.02% | $639.39 |
|
VCYT
Veracyte, Inc.
|
$124.9M | $0.32 | 11.04% | 511.28% | $47.50 |
|
XWEL
XWELL, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SHC
Sotera Health Co.
|
$17.70 | $18.93 | $5B | 91.71x | $0.00 | 0% | 4.39x |
|
FONR
FONAR Corp.
|
$14.53 | -- | $91.5M | 13.14x | $0.00 | 0% | 0.88x |
|
PRPH
ProPhase Labs, Inc.
|
$0.62 | $13.80 | $2.6M | -- | $0.00 | 0% | 0.42x |
|
TMO
Thermo Fisher Scientific, Inc.
|
$579.12 | $639.39 | $217.6B | 33.46x | $0.43 | 0.3% | 5.03x |
|
VCYT
Veracyte, Inc.
|
$42.92 | $47.50 | $3.4B | 113.07x | $0.00 | 0% | 6.89x |
|
XWEL
XWELL, Inc.
|
$0.62 | -- | $3.6M | -- | $0.00 | 0% | 0.11x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SHC
Sotera Health Co.
|
80.53% | 0.673 | 50.96% | 1.99x |
|
FONR
FONAR Corp.
|
18.59% | 1.654 | 49.09% | 9.64x |
|
PRPH
ProPhase Labs, Inc.
|
52.83% | -0.268 | 40.4% | 0.07x |
|
TMO
Thermo Fisher Scientific, Inc.
|
41.15% | 1.043 | 19.57% | 0.96x |
|
VCYT
Veracyte, Inc.
|
3.12% | 1.341 | 1.49% | 5.74x |
|
XWEL
XWELL, Inc.
|
278.04% | 1.263 | 65.46% | 0.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SHC
Sotera Health Co.
|
$174.5M | $125.4M | 1.98% | 11.79% | 40.29% | $33.4M |
|
FONR
FONAR Corp.
|
$10.4M | $3.2M | 4.68% | 5.84% | 12.26% | -$636K |
|
PRPH
ProPhase Labs, Inc.
|
-$650.5K | -$4.8M | -51.85% | -90.24% | -539.52% | -$3.5M |
|
TMO
Thermo Fisher Scientific, Inc.
|
$4.6B | $2.2B | 7.77% | 13.15% | 19.37% | $1.8B |
|
VCYT
Veracyte, Inc.
|
$89.4M | $23.1M | 2.43% | 2.52% | 17.53% | $42M |
|
XWEL
XWELL, Inc.
|
$1.3M | -$282K | -84.75% | -224.93% | -3.84% | -$3.1M |
Sotera Health Co. vs. Competitors
-
Which has Higher Returns SHC or FONR?
FONAR Corp. has a net margin of 15.55% compared to Sotera Health Co.'s net margin of 10.25%. Sotera Health Co.'s return on equity of 11.79% beat FONAR Corp.'s return on equity of 5.84%.
Company Gross Margin Earnings Per Share Invested Capital SHCSotera Health Co.56.04% $0.17 $2.8B FONRFONAR Corp.40.11% $0.34 $201.3M -
What do Analysts Say About SHC or FONR?
Sotera Health Co. has a consensus price target of $18.93, signalling upside risk potential of 6.94%. On the other hand FONAR Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Sotera Health Co. has higher upside potential than FONAR Corp., analysts believe Sotera Health Co. is more attractive than FONAR Corp..
Company Buy Ratings Hold Ratings Sell Ratings SHCSotera Health Co.5 3 0 FONRFONAR Corp.0 0 0 -
Is SHC or FONR More Risky?
Sotera Health Co. has a beta of 1.815, which suggesting that the stock is 81.485% more volatile than S&P 500. In comparison FONAR Corp. has a beta of 1.000, suggesting its less volatile than the S&P 500 by 0.021000000000004%.
-
Which is a Better Dividend Stock SHC or FONR?
Sotera Health Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. FONAR Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sotera Health Co. pays -- of its earnings as a dividend. FONAR Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SHC or FONR?
Sotera Health Co. quarterly revenues are $311.3M, which are larger than FONAR Corp. quarterly revenues of $26M. Sotera Health Co.'s net income of $48.4M is higher than FONAR Corp.'s net income of $2.7M. Notably, Sotera Health Co.'s price-to-earnings ratio is 91.71x while FONAR Corp.'s PE ratio is 13.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sotera Health Co. is 4.39x versus 0.88x for FONAR Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SHCSotera Health Co.4.39x 91.71x $311.3M $48.4M FONRFONAR Corp.0.88x 13.14x $26M $2.7M
-
Which has Higher Returns SHC or PRPH?
ProPhase Labs, Inc. has a net margin of 15.55% compared to Sotera Health Co.'s net margin of -774.52%. Sotera Health Co.'s return on equity of 11.79% beat ProPhase Labs, Inc.'s return on equity of -90.24%.
Company Gross Margin Earnings Per Share Invested Capital SHCSotera Health Co.56.04% $0.17 $2.8B PRPHProPhase Labs, Inc.-73.67% -$1.65 $14.5M -
What do Analysts Say About SHC or PRPH?
Sotera Health Co. has a consensus price target of $18.93, signalling upside risk potential of 6.94%. On the other hand ProPhase Labs, Inc. has an analysts' consensus of $13.80 which suggests that it could grow by 22339.02%. Given that ProPhase Labs, Inc. has higher upside potential than Sotera Health Co., analysts believe ProPhase Labs, Inc. is more attractive than Sotera Health Co..
Company Buy Ratings Hold Ratings Sell Ratings SHCSotera Health Co.5 3 0 PRPHProPhase Labs, Inc.0 0 0 -
Is SHC or PRPH More Risky?
Sotera Health Co. has a beta of 1.815, which suggesting that the stock is 81.485% more volatile than S&P 500. In comparison ProPhase Labs, Inc. has a beta of -0.657, suggesting its less volatile than the S&P 500 by 165.684%.
-
Which is a Better Dividend Stock SHC or PRPH?
Sotera Health Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sotera Health Co. pays -- of its earnings as a dividend. ProPhase Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SHC or PRPH?
Sotera Health Co. quarterly revenues are $311.3M, which are larger than ProPhase Labs, Inc. quarterly revenues of $883K. Sotera Health Co.'s net income of $48.4M is higher than ProPhase Labs, Inc.'s net income of -$6.8M. Notably, Sotera Health Co.'s price-to-earnings ratio is 91.71x while ProPhase Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sotera Health Co. is 4.39x versus 0.42x for ProPhase Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SHCSotera Health Co.4.39x 91.71x $311.3M $48.4M PRPHProPhase Labs, Inc.0.42x -- $883K -$6.8M
-
Which has Higher Returns SHC or TMO?
Thermo Fisher Scientific, Inc. has a net margin of 15.55% compared to Sotera Health Co.'s net margin of 14.58%. Sotera Health Co.'s return on equity of 11.79% beat Thermo Fisher Scientific, Inc.'s return on equity of 13.15%.
Company Gross Margin Earnings Per Share Invested Capital SHCSotera Health Co.56.04% $0.17 $2.8B TMOThermo Fisher Scientific, Inc.41.29% $4.28 $86.8B -
What do Analysts Say About SHC or TMO?
Sotera Health Co. has a consensus price target of $18.93, signalling upside risk potential of 6.94%. On the other hand Thermo Fisher Scientific, Inc. has an analysts' consensus of $639.39 which suggests that it could grow by 10.41%. Given that Thermo Fisher Scientific, Inc. has higher upside potential than Sotera Health Co., analysts believe Thermo Fisher Scientific, Inc. is more attractive than Sotera Health Co..
Company Buy Ratings Hold Ratings Sell Ratings SHCSotera Health Co.5 3 0 TMOThermo Fisher Scientific, Inc.17 5 0 -
Is SHC or TMO More Risky?
Sotera Health Co. has a beta of 1.815, which suggesting that the stock is 81.485% more volatile than S&P 500. In comparison Thermo Fisher Scientific, Inc. has a beta of 0.899, suggesting its less volatile than the S&P 500 by 10.144%.
-
Which is a Better Dividend Stock SHC or TMO?
Sotera Health Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Thermo Fisher Scientific, Inc. offers a yield of 0.3% to investors and pays a quarterly dividend of $0.43 per share. Sotera Health Co. pays -- of its earnings as a dividend. Thermo Fisher Scientific, Inc. pays out 9.43% of its earnings as a dividend. Thermo Fisher Scientific, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SHC or TMO?
Sotera Health Co. quarterly revenues are $311.3M, which are smaller than Thermo Fisher Scientific, Inc. quarterly revenues of $11.1B. Sotera Health Co.'s net income of $48.4M is lower than Thermo Fisher Scientific, Inc.'s net income of $1.6B. Notably, Sotera Health Co.'s price-to-earnings ratio is 91.71x while Thermo Fisher Scientific, Inc.'s PE ratio is 33.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sotera Health Co. is 4.39x versus 5.03x for Thermo Fisher Scientific, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SHCSotera Health Co.4.39x 91.71x $311.3M $48.4M TMOThermo Fisher Scientific, Inc.5.03x 33.46x $11.1B $1.6B
-
Which has Higher Returns SHC or VCYT?
Veracyte, Inc. has a net margin of 15.55% compared to Sotera Health Co.'s net margin of 14.51%. Sotera Health Co.'s return on equity of 11.79% beat Veracyte, Inc.'s return on equity of 2.52%.
Company Gross Margin Earnings Per Share Invested Capital SHCSotera Health Co.56.04% $0.17 $2.8B VCYTVeracyte, Inc.67.76% $0.24 $1.3B -
What do Analysts Say About SHC or VCYT?
Sotera Health Co. has a consensus price target of $18.93, signalling upside risk potential of 6.94%. On the other hand Veracyte, Inc. has an analysts' consensus of $47.50 which suggests that it could grow by 10.67%. Given that Veracyte, Inc. has higher upside potential than Sotera Health Co., analysts believe Veracyte, Inc. is more attractive than Sotera Health Co..
Company Buy Ratings Hold Ratings Sell Ratings SHCSotera Health Co.5 3 0 VCYTVeracyte, Inc.8 2 1 -
Is SHC or VCYT More Risky?
Sotera Health Co. has a beta of 1.815, which suggesting that the stock is 81.485% more volatile than S&P 500. In comparison Veracyte, Inc. has a beta of 1.829, suggesting its more volatile than the S&P 500 by 82.869%.
-
Which is a Better Dividend Stock SHC or VCYT?
Sotera Health Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sotera Health Co. pays -- of its earnings as a dividend. Veracyte, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SHC or VCYT?
Sotera Health Co. quarterly revenues are $311.3M, which are larger than Veracyte, Inc. quarterly revenues of $131.9M. Sotera Health Co.'s net income of $48.4M is higher than Veracyte, Inc.'s net income of $19.1M. Notably, Sotera Health Co.'s price-to-earnings ratio is 91.71x while Veracyte, Inc.'s PE ratio is 113.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sotera Health Co. is 4.39x versus 6.89x for Veracyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SHCSotera Health Co.4.39x 91.71x $311.3M $48.4M VCYTVeracyte, Inc.6.89x 113.07x $131.9M $19.1M
-
Which has Higher Returns SHC or XWEL?
XWELL, Inc. has a net margin of 15.55% compared to Sotera Health Co.'s net margin of -2.87%. Sotera Health Co.'s return on equity of 11.79% beat XWELL, Inc.'s return on equity of -224.93%.
Company Gross Margin Earnings Per Share Invested Capital SHCSotera Health Co.56.04% $0.17 $2.8B XWELXWELL, Inc.17.32% -$0.26 $13M -
What do Analysts Say About SHC or XWEL?
Sotera Health Co. has a consensus price target of $18.93, signalling upside risk potential of 6.94%. On the other hand XWELL, Inc. has an analysts' consensus of -- which suggests that it could grow by 1025.04%. Given that XWELL, Inc. has higher upside potential than Sotera Health Co., analysts believe XWELL, Inc. is more attractive than Sotera Health Co..
Company Buy Ratings Hold Ratings Sell Ratings SHCSotera Health Co.5 3 0 XWELXWELL, Inc.0 0 0 -
Is SHC or XWEL More Risky?
Sotera Health Co. has a beta of 1.815, which suggesting that the stock is 81.485% more volatile than S&P 500. In comparison XWELL, Inc. has a beta of 1.227, suggesting its more volatile than the S&P 500 by 22.697%.
-
Which is a Better Dividend Stock SHC or XWEL?
Sotera Health Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sotera Health Co. pays -- of its earnings as a dividend. XWELL, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SHC or XWEL?
Sotera Health Co. quarterly revenues are $311.3M, which are larger than XWELL, Inc. quarterly revenues of $7.3M. Sotera Health Co.'s net income of $48.4M is higher than XWELL, Inc.'s net income of -$211K. Notably, Sotera Health Co.'s price-to-earnings ratio is 91.71x while XWELL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sotera Health Co. is 4.39x versus 0.11x for XWELL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SHCSotera Health Co.4.39x 91.71x $311.3M $48.4M XWELXWELL, Inc.0.11x -- $7.3M -$211K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
56
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
